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Background: Metabolomics is an emerging ﬁeld that includes ascertaining a metabolic proﬁle from a
combination of small molecules, and which has health applications. Metabolomic methods are currently
applied to discover diagnostic biomarkers and to identify pathophysiological pathways involved in pathol-
ogy. However, metabolomic data are complex and are usually analyzed by statistical methods. Although
the methods have been widely described, most have not been either standardized or validated. Data anal-
ysis is the foundation of a robust methodology, so new mathematical methods need to be developed to
assess and complement current methods. We therefore applied, for the ﬁrst time, the dominance-based
rough set approach (DRSA) to metabolomics data; we also assessed the complementarity of this method
with standard statistical methods. Some attributes were transformed in a way allowing us to discover glo-
bal and local monotonic relationships between condition and decision attributes. We used previously pub-
lished metabolomics data (18 variables) for amyotrophic lateral sclerosis (ALS) and non-ALS patients.
Results: Principal Component Analysis (PCA) and Orthogonal Partial Least Square-Discriminant Analysis
(OPLS-DA) allowed satisfactory discrimination (72.7%) between ALS and non-ALS patients. Some discrim-
inantmetabolites were identiﬁed: acetate, acetone, pyruvate and glutamine. The concentrations of acetate
and pyruvatewere also identiﬁed by univariate analysis as signiﬁcantly different betweenALS andnon-ALS
patients. DRSA correctly classiﬁed 68.7% of the cases and established rules involving some of the metabo-
lites highlighted by OPLS-DA (acetate and acetone). Some rules identiﬁed potential biomarkers not
revealed by OPLS-DA (beta-hydroxybutyrate). We also found a large number of common discriminating
metabolites after Bayesian conﬁrmation measures, particularly acetate, pyruvate, acetone and ascorbate,
consistent with the pathophysiological pathways involved in ALS.
292 H. Blasco et al. / Journal of Biomedical Informatics 53 (2015) 291–299Conclusion: DRSAprovides a complementarymethod for improving the predictive performance of themul-
tivariate data analysis usually used inmetabolomics. Thismethod could help in the identiﬁcation ofmetab-
olites involved in disease pathogenesis. Interestingly, these different strategies mostly identiﬁed the same
metabolites as being discriminant. The selection of strong decision rules with high value of Bayesian con-
ﬁrmation provides useful information about relevant condition–decision relationships not otherwise
revealed in metabolomics data.
 2014 Elsevier Inc. All rights reserved.1. Background
Metabolomics is deﬁned as the study of all metabolites in a sys-
tem, and includes the identiﬁcation of metabolic signatures from a
combination of small molecules in biological ﬂuid. This emerging
‘‘omics’’ approach is increasingly used in medicine to ﬁnd diagnos-
tic and prognostic biomarkers of diseases and to identify patho-
physiological pathways involved in these pathologies. The
methods involve studying metabolites across a large spectrum of
concentrations, polarity and masses [1–3], based on high-
throughput techniques [4]. ‘‘Untargeted’’ metabolomics is based
on metabolic proﬁles without systematic identiﬁcation of metabo-
lites included in this proﬁle, and ‘‘targeted’’ methodologies focus
on speciﬁc metabolites. Whatever the approach, data preprocess-
ing and analysis are the foundation of a robust methodology. There
has been increasing work in bioinformatics to try to standardize
these steps [5–8]. The greatest risk associated with high-
throughput techniques is mishandling multiple and complex data,
leading to biased results. Multivariate statistical analysis including
Principal Component Analysis (PCA: the aims of which include
description) and Orthogonal Partial Least Squares Discriminant
Analysis (OPLS-DA: for predictions) are the most widely used sta-
tistical methodologies in ‘‘omics’’ studies. However, standard crite-
ria to validate the models are often unavailable. Efforts have to be
made to validate the models statistically or to validate this strategy
using another mathematical approach. Internal validation based on
cross-validation with the current cohort is the most common strat-
egy; external validation based on experiments performed on
another platform using samples from a different origin is rare.
Consequently, it would be valuable to test different methods of
statistical treatment to assess the similarity of the biomarkers
identiﬁed and the performance of predictive models. Also, it would
be helpful to provide the proof of concept that different mathemat-
ical tools could be used to analyze metabolomics data.
Knowledge discovery from data describing a piece of the real or
an abstract world is a ﬁeld of computer science: it involves the pro-
cess of searching the data automatically for patterns that can be
considered knowledge about this piece of the world. The patterns
are evidenced by induction some ‘‘condition–decision’’ relation-
ships hidden in the data. The most natural representation of these
relationships is by ‘‘if...,then...’’ decision rules relating some condi-
tions on independent variables (called condition attributes) to
some decisions on a dependent variable (called the decision
attribute). The same representation of patterns is used in multi-
attribute classiﬁcation, and therefore the data searched for
discovery of these patterns can be seen as classiﬁcation data.
In this paper, we analyze metabolomics data using the standard
descriptive and predictive methodologies (PCA and OPLS-DA). We
also adopt the classiﬁcation perspective to apply an original meth-
odology based on dominance-based rough set approach (DRSA) to
induction of ‘‘condition-decision’’ relationships from the data and
representing them by so-called monotonic decision rules. The
DRSA was never applied to metabolomics. Consequently, weassessed the complementarity and the usefulness of the novel con-
cept of analyzing metabolomics data by DRSA; this included test-
ing for the potential concordance of results between DRSA and
standard statistical methods of metabolomics data treatment, par-
ticularly in the identiﬁcation of relevant variables (condition attri-
butes). We used some data from targeted metabolomics
investigations: 1H Nuclear Magnetic Resonance (NMR) analysis of
cerebrospinal ﬂuids (CSF) from patients with amyotrophic lateral
sclerosis (ALS) and non-ALS patients. Some of these data were pub-
lished previously [9]. The ultimate aims of this project were to dis-
criminate ALS patients and non-ALS subjects, and to identify the
variables relevant for this discrimination.
This study is the ﬁrst to apply the DRSA to the analysis of met-
abolomics data and to assess the ‘‘added value’’ of this method over
standard statistical methods.2. Methods
2.1. Sample collection and NMR acquisition
The methodology for collection, handling and analysis of CSF
samples and for NMR acquisition has been described elsewhere
[9]. Brieﬂy, we collected 50 samples from ALS patients at the time
of diagnosis and 49 from non-ALS subjects. Information on age at
onset and gender were obtained for each subject. The 1H NMR
spectra were acquired with a Bruker DRX-500 spectrometer (Bru-
ker SADIS, Wissembourg, France). Data were processed using
XWinNMR version 3.5 software (Bruker Daltonik, Karlsruhe, Ger-
many). Metabolite peaks were determined with the ERETIC peak
as a quantitative reference.
We quantiﬁed (by XWin NMR software) 17 CSF metabolites in
ALS and non ALS patients, deﬁned as follows: amino-acids (alanine,
glutamine, tyrosine), organic acids (citrate, acetate, a-hydroxybu-
tyrate (AHBT)), ketone bodies (b-hydroxybutyrate (BHBT), acetone,
acetoacetate), glucose, fructose, metabolites involved in glucose
metabolism (pyruvate, lactate), creatinine and creatine, recently
identiﬁed as markers of mitochondrial dysfunction [10], the anti-
oxidant molecule ascorbate, formate, and ethanol. Thus, we
obtained the following data for each subject: age, gender, concen-
trations of the CSF metabolites (additional ﬁle 1).2.2. Univariate analysis
Wilcoxon tests and t-tests were used to compare CSF metabo-
lite concentrations between ALS and non ALS patients to identify
disturbances in metabolic pathways associated with ALS. We also
compared sex and age between the two groups. A correction for
multiple tests (Bonferroni adjustment) was applied to adjust the
p values by accounting for the 19 parameters evaluated in the anal-
ysis. Differences were considered as signiﬁcant when p < 0.0026.
JMP statistical software version 7.0.2 (SAS Institute, Cary, North
Carolina) was used for all statistical analyses.
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Multivariate analysis was performed on metabolomics data
using Simca-P+-13. We used Pareto scaling (Par), obtained by
dividing each variable by the square root of its standard deviation.
Logarithmic transformation was used to minimise the impact of
both noise and high variance of the variables [11]. After these
transformations, data were used for unsupervised principal com-
ponents analysis (PCA) [12] to identify similarities or differences
between sample proﬁles. PCA uses a vector space transform to
reduce the dimensionality of large data sets. The starting point
for PCA is a matrix of data characterized by N observations (rows)
and X variables (columns). PCA is used to represent a multivariate
data table as a low-dimensional plane to provide an overview of
the data. Thus, it reveals groups of observations, trends, and outli-
ers, and uncovers the relationships between observations and
variables, and between variables themselves. PCA ﬁnds lines,
planes, and hyperplanes in the X-dimensional space that approxi-
mate the data in the least square sense.
Spectral variation was reduced to a series of principal compo-
nents (PC), each representing correlated spectral differences, and
summarized in a score plot. PCs, new variables that are orthogonal
to each other, explained progressively less variance in the data set.
The PCs were displayed in a two-dimensional score plot, allowing
visualization of the distribution and grouping of the samples in the
new variable space. Score plots were inspected visually for group-
ing, trends in the data. The goodness of ﬁt explains how well we
are able to reproduce mathematically the data of the data set. A
quantitative measure of the goodness of ﬁt is given by the
parameter R2X (=the explained variation, goodness of ﬁt) and the
predicted variation Q2X (goodness of prediction).
2.4. Orthogonal partial least square-discriminant analysis
Orthogonal projections to latent structures (OPLS) is a modiﬁca-
tion of the PLS regression analysis method. The OPLS method can
separate the systematic variation in the X variable into two parts:
(1) that which is linearly related to Y, and (2) that which is orthog-
onal to Y. Both PLS and OPLS methods are supervised statistical
methods whereas PCA is not. Supervised and unsupervised model-
ing techniques are suitable for metabolomics because they can
manage large numbers of variables for small sample sizes and
simultaneously be able to take into account multicollinearity and
missing values. Orthogonal partial least-squares discriminant anal-
ysis (OPLS-DA) evaluates variations in frame areas between
groups: variation in the measured data can be partitioned into
two blocks by the program, one containing variations that correlate
with the class identiﬁer and the other containing variations that
are orthogonal to the ﬁrst block and thus do not contribute to dis-
crimination between the groups [13]. Next, we created a score plot
to visualize the OPLS-DA model and characterize the contribution
of variables to the separation of classes using the loading plot
and the contribution plot. The contribution plot of scores shows
variation which is explained, i.e., which variables contribute to
the model. OPLS-DA was cross validated by withholding one-
seventh of the samples in seven successive simulations such that
each sample was omitted once to guard against over ﬁtting [14].
This approach meant that the OPLS-DA was built from one
‘‘predictive’’ component and two or more orthogonal components.
Q2 and R2 indicate the robustness of the model. R2 is deﬁned as a
fraction of the variance explained by a component. Cross validation
of R2 gives Q2, which represents the proportion of total variation
predicted by a component. Thus, the R2 indicates how well the var-
iation of a variable is explained and Q2 howwell a variable could be
predicted and estimated by cross validation (i.e., the accuracy of
prediction). We evaluated the Q2/R2 overview plot to identify thecumulative R2 and Q2 values for each variable. Metabolites that
are well modeled have R2 and Q2 values > 0.5. The predicted data
were then compared with the original data and the sum of squared
errors calculated for the whole dataset. This is called the Predicted
Residual Sum of Squares (PRESS), and low values of PRESS indicate
good prediction by the model. For convenience, we then converted
PRESS into Q2 to resemble the scale of the R2: PRESS were divided
by the initial sum of squares and subtracted from 1. Good predic-
tions have low PRESS and therefore high Q2.
The quality of the models is described by the cumulative
modeled variation in the X matrix (metabolites) or R2X(cum), the
cumulative modeled variation in the Y matrix (CSF samples) or R2-
Y(cum), and the cross validated predictive ability or Q2(cum) val-
ues. Models were rejected if there was complete overlap of Q2
distributions (Q2(cum) < 0) or low classiﬁcation rates
(Q2(cum) < 0.05 and eigenvalues > 2). We considered a model
robust if Q2 > 40% and R2 > 50%, but the relevance of these cut off
values needs to be conﬁrmed under biological conditions. The set
of multiple models resulting from the cross validation was used
to calculate jack-knife uncertainty measures [15]. The jack-knife
method is a non-parametric method widely used for estimating
the sampling distribution of a statistic. Given a sample dataset
and a desired statistic, the jack-knife works by computing the
desired statistic with an element removed from the equation. Thus,
jack-knife standard error of the predicted scores is computed from
all the cross validation rounds.
The predicted data were then compared with the original data
and the sum of squared errors calculated for the whole dataset.
We ﬁxed the maximum number of iterations at 200 to ensure con-
vergence of the OPLS algorithm [16]. A misclassiﬁcation table was
generated to show the proportion of correctly classiﬁed observa-
tions in the dataset (ALS vs non-ALS patients). We evaluated the
performance of the predictive model using sensitivity, speciﬁcity,
positive predictive value (PPV) and negative predictive value
(NPV). We also calculated the Matthews correlation coefﬁcient to
evaluate the prediction. We built the models from the 17 metabo-
lites and age (18 independent variables). The Variable Importance
Parameter (VIP) values summarize the overall contribution of each
X-variable to the model, summed over all components and
weighted according to the Y variation accounted for by each com-
ponent. Thus, VIP ranks the compounds (metabolites) according to
their contribution to the model, and variable selection ensured the
involvement of the most relevant VIP in the ﬁnal model.
We also drew a Receiver Operating Characteristic (ROC) curve
from the Ypred values obtained with the best OPLS-DA model.
We calculated the cut-off of the YPred value and the associated
sensitivity and speciﬁcity for classifying ALS patients.
2.5. Dominance-based rough set approach (DRSA)
Data from targeted metabolomics investigations of cerebrospi-
nal ﬂuids from ALS patients and non-ALS subjects can be consid-
ered to be classiﬁcation data, where concentrations of particular
metabolites are condition attributes (independent variables), and
ALS or non-ALS are class labels assigned to individuals by a deci-
sion attribute (dependent variable). To explain the class assign-
ment in terms of condition attributes, we used the rough set
concept [17], and its particular extension called Dominance-based
rough set approach (DRSA) [18–21]. DRSA proved to be an effective
tool in analysis of classiﬁcation data which are partially inconsis-
tent [22,23]. In the context of our study, inconsistency means that
two individuals have similar concentrations of metabolites
although one is in the ALS class, and the other is in the non-ALS
class. The rough sets representing ALS and non-ALS classes discern
between consistent and inconsistent individuals and prepare the
ground for induction of decision rules. DRSA assumes that the
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dependent on the order of decision classes. As a consequence, the
rules derived from data structured using the concept of the DRSA
are monotonic, which means that they have the following syntax:
‘‘if ati(patient)P vali and atj(patient)P valj and . . . and
atp(patient)P valp, then patient is ALS’’,
‘‘if atk(patient)6 valk and atl(patient) 6 vall and . . . and
ats(patient) 6 vals, then patient is non-ALS’’,where ath is an h-th
condition attribute and valh is a threshold value of this attribute
which makes an elementary condition ath(patient)P valh or
ath(patient) 6 valh entering the condition part of a rule indicating
the assignment of a patient to either class ALS or non-ALS, respec-
tively. In the above syntax of the rules, it is assumed that value sets
of all condition attributes are numerical and ordered such that the
greater the value, the more likely it is that the patient is ALS; anal-
ogously, it is assumed that the smaller the value, the more likely it
is that the patient is non-ALS. Attributes ordered in this way are
called gain-type. Cost-type attributes have value sets ordered in
the opposite direction, such that elementary conditions on these
attributes have opposite relation signs. In case of metabolomics
data, it is not possible to know a priori if concentrations of metab-
olites are gain or cost attributes, and therefore we proceeded as
described in [24]: each original attribute is considered in two cop-
ies, with the ﬁrst copy assumed to be gain-type, and the second
cost-type. The applied transformation of data is non-invasive, i.e.,
it does not bias the relationships identiﬁed between condition
attributes and the decision attribute. Then, the induction algorithm
constructs decision rules involving elementary conditions on one
or both copies of particular attributes. For example, for a rule indi-
cating the assignment of a patient to class ALS, the following ele-
mentary conditions concerning attribute ati may appear:
 "ati(patient)P vali1,
 ;ati(patient)6 vali2,
 "ati(patient)P vali1 and ;ati(patient) 6 vali2, which boils down
to ati(patient) 2 [vali1, vali2,] if vali1 < vali2,
where "ati and ;ati are gain-type and cost-type copies of attribute
ati, respectively. Note that this transformation of attributes allows
global and local monotonic relationships between concentration of
metabolites and class assignment to be discovered. The monotonic
relationship is global when it can be expressed by a single elemen-
tary condition concerning gain-type or cost-type attribute. Local
monotonicity relationship requires conjunction of two elementary
conditions of different type. In case of assignment of a patient to
class ALS we can have such a local monotonicity relationship,
e.g., when concentration of metabolite is below a certain point,
the greater the value the better the assignment, but after that point
further increase may have a negative effect (i.e., the lower the
value the better the assignment).
Rules are characterized by their strength deﬁned as a ratio of
the number of patients matching the condition part of the rule to
the total number of patients in the sample.
Sets of decision rules, which are essential for the analysis, were
induced from metabolomics data transformed as described above
and structured according to the DRSA. The induction algorithm is
called VC-DomLEM [25]; it was implemented as a software pack-
age called jMAF (http://idss.cs.put.poznan.pl/site/139.html), based
on the java Rough Set (jRS) library. The sets of rules induced were
used to construct component classiﬁers in variable consistency
bagging [26,27]. Variable consistency bagging (VC-bagging) was
applied to increase the accuracy of results produced by VC-
DomLEM. Both rule relevance and attribute relevance in rules were
estimated by measuring Bayesian conﬁrmation, as described in
[28]. In this process, decision rules are induced repetitively on
bootstrap samples and tested with data from individuals who were
not included in the samples. Let us interpret a rule as aconsequence relation ‘‘if E, then H’’, where E denotes rule premise,
and H rule conclusion. For rule relevance, the Bayesian
conﬁrmation measure quantiﬁes the contribution of rule premise
E to correct classiﬁcation of unseen individuals. Many Bayesian
conﬁrmation measures have been described in the literature, of
which we used the measure s(H, E). This approach allows clear
interpretation in terms of a difference of conditional probabilities
involving H and E, i.e., s(H, E) = Pr(H|E)Pr(H|E), where probability
Pr() is estimated from the test samples of patients. For the rele-
vance of single attributes, the Bayesian conﬁrmation measure
quantiﬁes the degree to which the presence of attribute ati in pre-
mise E, denoted by ati. E, provides evidence for or against conclu-
sion H of the rule. Here, we again used measure s(H, ati.E), which,
in this case, is deﬁned as follows, s(H, ati.E) = Pr(H|ati.E)  Pr(H|ati-
.E). Consequently, attributes present in the premise of a rule that
assigns patients correctly, or attributes absent from the condition
part of a rule that assigns patients incorrectly, are indicated as
more relevant.2.6. Comparison of the data analysis methods
We assessed the percentages of predictions that were correct
for OPLS-DA models and DRSA. The VIP identiﬁed by the PCA and
OPLS-DA models were compared with the metabolites found to
be important by the rules established from DRSA. Unfortunately,
we could not perform a robust cross-validation between these
methods because numerous parameters are not available for mod-
iﬁcation using SIMCA software and we were not able to parameter
all the same criteria for DRSA and OPLS-DA models.3. Results and discussion
3.1. Univariate analysis
There was no signiﬁcant difference in mean age between the
groups (59.7 ± 10.6 years for ALS patients vs. 63.9 ± 14.5 years for
non-ALS individuals, p = 0.09). The percentage of men was similar
in the two groups (64% in the ALS group vs. 55.10% in the non-
ALS group, p = 0.41). The concentrations of acetate were lower
(mean ± SD: 174 ± 159 lmol/L vs. 84 ± 101 lmol/L (p < 0.0001))
in ALS patients than non-ALS individuals. After Bonferroni adjust-
ment, there was a trend for the acetone concentration to be higher
in ALS patients (13.4 ± 12.2 lmol/L vs. 8.7 ± 8.2 lmol/L, p = 0.02).
There was a trend for the glutamine concentration to be lower in
ALS patients (652 ± 225 vs. 790 ± 348, p = 0.03). The concentrations
of pyruvate were higher (58 ± 37 lmol/L vs. 39 ± 48, p = 0.0026) in
ALS patients than in non-ALS individuals. A color map was gener-
ated from the p-values for correlations between variables and
revealed that all the variables were highly correlated (Additional
ﬁle 2).3.2. PCA
The resulting PCA score plot showed that the two ﬁrst PCs
explained 64.1% of the variation of the selected metabolites
(Fig. 1A). ALS and non-ALS individuals formed separate clusters
in the PCA scores plot of the quantitative data. To summarize, each
spectrum can be viewed as an observation in the PCA space where
the proximity of observations represents the similarity of the met-
abolic proﬁles of CSF samples. The contribution score plot (Fig. 1B)
identiﬁed the relative importance of each variable to differentiat-
ing ALS from non-ALS individuals. The Q2/R2 overview plot
indicated that 76.4% of the metabolites were well modeled
(Additional ﬁle 3).
Fig. 1. Principal component analysis of 18 variables for ALS patients (A) and non-ALS subjects (B). Principal component analysis of 18 variables (17 metabolites and age), A:
score plot for ALS (n = 50, yellow dots) and non-ALS patients (n = 49, green dots) and B: Contribution plot from the model including the 18 variables. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
H. Blasco et al. / Journal of Biomedical Informatics 53 (2015) 291–299 2953.3. OPLS-DA
The performance of the model including the 17 metabolites and
age was satisfactory: prediction was correct in 72.73% of cases
(sensitivity: 78%; speciﬁcity: 67.3%; PPV: 70.9%; NPV: 75.0%; addi-
tional ﬁle 4). The Matthews correlation coefﬁcient for the diagnosis
prediction using these data was 0.46. Handling of metabolomics
data is based on the optimization of the predictive model through
the selection of variables. This approach provides the best perfor-
mance criteria of the models. As the number of variables is high
with respect to the size of the cohort, the maximal reduction of
the number of metabolites selected leads to the most rigorous
results.From the predictive variation between X (metabolites, age) and
Y (CSF samples) given by R2X(cum), the best model used four com-
ponents, and interpreted approximately 99.9% of the total variation
in X. Pareto scaling of the models created by OPLS-DA (Fig. 2A),
explained approximately 24.5% of the variations in the various
samples (R2Y(cum)). We found the predictive value of the models
to be low (Q2(cum) = 0.167). The cross-validation performance
was conﬁrmed by analysis of variance (CV-)ANOVA (median p-
value = 0.021). The contribution score plot (Fig. 2B) identiﬁed the
relative importance of each compound to differentiating ALS from
non-ALS individuals, and showed that high levels of acetone and
pyruvate, and low levels of glutamine and acetate allowed discrim-
ination. The loading scatter plot (Fig. 3) showing which variables
Fig. 2. OPLS-DA model obtained from four VIP including scores scatter plot (A) and contribution plot (B). OPLS-DA model obtained from four VIP (acetone, pyruvate, acetate
and glutamine), A: Score scatter plot of the ﬁrst principal component (yellow dot: ALS patients, n = 50; and green dots: non-ALS subjects; n = 49), R2X(cum) = 0.999,
R2Y(cum) = 0.245, and Q2(cum) = 0.167, B: Contribution plot from model including these four VIP, peaks with positive contribution scores correspond to metabolites with
higher levels in ALS (pyruvate, acetone), and those having negative contribution score correspond to metabolites with higher levels in non-ALS subjects (acetate, glutamine).
(For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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ﬁrmed these results. The VIP panel including these four metabo-
lites predicted the diagnostic group with mean probability of
76.8%, with 82% speciﬁcity, 72% sensitivity, 80% PPV, and 74.1
NPV. The Matthews correlation coefﬁcient for the diagnosis predic-
tion using these data was 0.54. Although the performance criteria
of the model are not excellent, the predictive ability of the model
is satisfactory. The AUC value obtained from the ROC curve is
0.79 and deﬁnes a cut-off was a sensitivity of 90% and speciﬁcity
of 69.5%. Note that there is currently no diagnostic biomarker for
this disease. Despite the percentage of predictions that are correct
is only moderate, this methodology nevertheless represents signif-
icant progress. However, this strategy is highly optimistic: ﬁtting a
PLS model using VIP identiﬁed in a previous step corresponds to
statistical variable selection coupled with a PLS predictor. This
strategy provides artiﬁcially optimistic cross-validation results, as
the Q2 value is derived only for the second PLS model alone, notfor the combined two-step ‘‘variable selection + PLS predictor’’
model.
Nevertheless, the metabolites identiﬁed as discriminative were
the same as those identiﬁed by univariate analysis as being signif-
icantly different or having a trend toward being different between
the two groups (including, glutamine and acetone).
3.4. Dominance-based rough set approach
The model constructed by VC-bagging with VC-DomLEM com-
ponent classiﬁers showed good classiﬁcation performance in
threefold stratiﬁed cross validation, which was repeated 100 times
for a better repeatability. On average, 68.7% of cases were correctly
classiﬁed (sensitivity: 70%, and speciﬁcity: 67.3%, Matthews corre-
lation coefﬁcient: 0.37). The values of the Bayesian conﬁrmation
measure calculated for all variables (condition attributes) gave
more insight into the constructed classiﬁcation model (Fig. 4).
Fig. 3. Loading score plot from the model based on four VIP. Loading score plot from the model based on four VIP. Scatter plot of the X- and Y-loadings. This plot shows how
the responses (Y’s) varied in relation to each other, i.e. which provided similar information, and their relationship to the terms of the model.
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Fig. 4. Bayesian conﬁrmation measure computed for each of 18 variables. Bayesian conﬁrmation measure computed for each of 18 variables (condition attributes). This plot
shows how each of the variables used in the DRSA model conﬁrms correct classiﬁcation of ALS patients.
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which are the most relevant from the viewpoint of correct predic-
tion by the DRSA rule model. Importantly, we found that the
metabolites identiﬁed as the most relevant by the Bayesian conﬁr-
mation were the same as those revealed to be discriminative by
univariate analysis and OPLS-DA.
The rules induced from the information table structured using
DRSA represent relevant patterns of condition–decision relation-
ships, which are free of inessential and redundant information.
Some of the most relevant of all the rules that constitute the DRSA
model are as follows.
1: if AcetateP 0.125 and Ascorbate 6 0.01964669 then patient
is not ALS;
{strength: 0.21, conﬁrmation s = 0.57}
2: if GlnP 0.804629579 and Acetone 6 0.007626821 then
patient is not ALS;
{strength: 0.11, conﬁrmation s = 0.37}
3: if Pyruvate 6 0.029593053 and CrnP 0.192354842 then
patient is not ALS;{strength: 0.09, conﬁrmation s = 0.2}
4: if Acetate 6 0.055457394 and Ascorbate 6 0.0786 then
patient is ALS;
{strength: 0.25, conﬁrmation s = 0.55}
5: if Acetone 2 [0.0087; 0.009534583] then patient is ALS;
{strength: 0.04, conﬁrmation s = 0.5}
6: Alanine 6 0.039024531 and PyruvateP 0.0326 then patient
is ALS;
{strength: 0.08, conﬁrmation s = 0.55}3.5. Comparison of results obtained using different approaches
The different approaches all led to identiﬁcation of the same
metabolites as being relevant. Although the parameters of internal
validation are different, including the number of repetitions and
the content of validation samples, the performance (correct predic-
tion percentage) and the relevance of the ﬁndings (metabolites
identiﬁed) are very similar.
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those by the OPLS-DA model, and are satisfactory for a disease of
this complexity. Note, however, that one of the limitations of
OPLS-DA is that the internal validation may be too optimistic
(additional ﬁle 5).
According to the descriptive methods of the DRSA, the most
relevant metabolites for explaining ALS are low concentration of
acetate (<55 lmol/L in the rules, and the median is 88 lmol/L),
and high concentration of pyruvate (>32.6 lmol/L in the rules
and the median is 34.9 lmol/L); although, alanine was not relevant
in the PCA and was not identiﬁed as signiﬁcantly different between
ALS and non-ALS groups by univariate analysis, it appears to be
important when associated with high levels of pyruvate. We also
found the same metabolites, with an inverse relationship to those
for ALS, to be relevant to describing non-ALS: DRSA conﬁrmed the
relevance of high acetate and low ascorbate concentrations for the
non-ALS group; and high concentrations of glutamine associated
with low concentrations of acetone were relevant to explain the
non-ALS patients. Although creatine–creatinine were not found
to be relevant by the PCA and did not differ statistically signiﬁ-
cantly between ALS and non-ALS groups in univariate analysis, this
metabolite pair appears important when associated with low lev-
els of pyruvate. This further implicates pyruvate in the pathogene-
sis of ALS. These ﬁndings are consistent with the hypothesis that
ALS is associated with a disturbance in glucose metabolism
[9,29,30].
Some metabolites, for example beta-hydroxybutyrate, are
involved in a large number of the rules obtained from DRSA
(additional ﬁle 6). Surprisingly, beta-hydroxybutyrate was not
identiﬁed as relevant by other methods. However, this ﬁnding is
entirely consistent with the involvement of acetate and acetone
in the predictive models. All these metabolites are ketone bodies,
as demonstrated by Kumar et al. [31] in a metabolomics study with
serum from ALS patients. Interestingly, some variables are involved
in some rules but the range of values are opposite, dependent on
the other variables associated in this rule (for example, predictive
rules to explain the pathology include high values of beta-
hydroxybutyrate when associated with high values of acetone
but also low values of beta-hydroxybutyrate when associated with
high values of ascorbate). Such observations may be very useful for
the interpretation of biochemical pathways, because they reveal
the dynamism and the kinetics of the overall metabolism.
Second, we also found a large number of common discriminat-
ing metabolites after Bayesian conﬁrmation measures were com-
puted for each of 18 variables: they include acetate, pyruvate,
acetone and ascorbate. Although ascorbate was not highly discrim-
inative in the ﬁnal OPLS-DA model, the concentration of ascorbate
tends to be higher in ALS patients and it is the third most impor-
tant metabolite in the OPLS-DA model including all variables. The
involvement of ascorbate, considered to be an anti-oxidant com-
pound, is consistent with the oxidative stress associated with the
pathogenesis of ALS [32,33].
The dominance-based rough set approach (DRSA) provides a
complementary means for analyzing metabolomics data. It could
be useful as a diagnostic tool, complementary to the models
already widely used in the ﬁeld of metabolomics and other
investigative techniques, particularly clinical and/or imaging
explorations. Above all, this approach could help identify metabo-
lites involved in the pathogenesis of a disease. This work provides
the proof of concept that diverse mathematical tools can contrib-
ute to the analysis of metabolomics data. In particular, the ability
to suggest mechanistic explanations about pathophysiological
pathways is promising. DRSA seems to be more suitable than SIM-
CA methods for interpreting relevant metabolites, and the relation-
ships between metabolites and particular subgroups of patients.
Moreover, the possibility of establishing strong decision rules withhigh value of Bayesian conﬁrmation provides useful information
about relevant condition–decision relationships hidden in meta-
bolomics data. Thus, we suggest that both methods are useful
and may be applied separately or together, depending on the
objectives of the study: prediction of diagnosis or elucidating path-
ophysiological pathways.Authors’ contributions
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correction.Appendix A. Dominance-based rough set approach
In the dominance-based rough set approach (DRSA) [22],
information about objects from set U (targeted metabolomics of
cerebrospinal ﬂuids from ALS and non-ALS subjects) is represented
in the form of an information table. In the set of attributes there is
a set A of condition attributes and a single decision attribute.
Condition attributes whose value sets are ordered are called ordi-
nal attributes. Without loss of generality, for ordinal attribute at
2 A, u: U? R, for all objects x, y 2 U, u(x)P u(y) means ‘‘x is eval-
uated at least as high as y on ordinal attribute at’’. Decision attri-
bute d is also ordinal. Values of d make a partition of U into a
ﬁnite number of decision classes, X = {Xt, t = 1, . . ., n}, such that
each x 2 U belongs to one and only one class Xt 2 X. It is supposed
that the classes are ordered, i.e., for all r, s 2 {1, . . ., n}, such that
r > s, the objects from Xr are in a higher class than those from Xs.
In general, ordinal attribute may have positive or negative
monotonic relationship with the decision attribute d (which is also
ordinal). A positive relationship means that the greater the value of
the condition attribute the higher the class label (i.e. the value of
the decision attribute), and a negative relationship means that
the greater the value of the condition attribute the lower the class
label. The ordinal classiﬁcation problem, for which positive or
negative monotonic relationships between ordinal condition
H. Blasco et al. / Journal of Biomedical Informatics 53 (2015) 291–299 299attributes and the decision attribute are present, is called ordinal
classiﬁcation with monotonicity constraints.Appendix B. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jbi.2014.12.001.References
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